FOCUS ON: TYPE 2 DIABETES AND RAMADAN
The management of type 2 diabetes during Ramadan
Many Muslim patients with type 2 diabetes may choose to fast for Ramadan, despite being medically exempt.1 What should you do next if your patient still chooses to fast? |
Explore written and video resources from subject matter experts, designed to support you in managing adults with type 2 diabetes over the fasting period. |
Key points to discuss 6-8 weeks prior to Ramadan with your patients wishing to fast may include2:
- Fluid intake and meal planning
- Exercise
- Frequency of blood glucose monitoring
- Medication adjustments
- When to break the fast
- Risk quantification
Download this patient leaflet to help individuals with T2D understand the risks and mitigation strategies when fasting during Ramadan
WEBINAR SUMMARY VIDEO | 13 MINS
A case-based approach to the practical management of type 2 diabetes during Ramadan | Alia Gilani
Jardiance® (empagliflozin) prescribing information for the UK
Agenda:
Goals of care for patients with T2D wishing to observe Ramadan
Guidance on managing type 2 diabetes in adult patients during periods of fasting, including medication recommendations and sick days
Application of strategies to fictional patient cases
SUMMARY DOCUMENT
A case-based approach to the practical management of type 2 diabetes during Ramadan
Includes:
The key risks associated with fasting for Ramadan in people living with type 2 diabetes
A summary of how to adjust medication doses for fasting individuals with T2D
3 fictional patient cases
Abbreviation:
T2D: type 2 diabetes
References:
- Hassanein M, et al. Curr Med Res Opin. 2024;40(9):1515-1523.
- International Diabetes Federation. Diabetes and Ramadan Practical Guidelines. 2021. Available at: https://idf.org/media/uploads/2024/07/IDF_DaR_Practical_Guidelines_Ramadan.pdf (accessed January 2026).
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
Jardiance is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
as monotherapy when metformin is considered inappropriate due to intolerance
in addition to other medicinal products for the treatment of diabetes
Jardiance is indicated in adults for the treatment of chronic kidney disease.
Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure.
PC-GB-112161 | January 2026